- ►eje.org P Iglesias, JJ Diez - European Journal of Endocrinology, 2006 - eje.org Type 2 diabetes is a well recognised cause of chronic renal failure (CRF). Only
few oral antidiabetic drugs can be used for treating type 2 diabetes in patients
with CRF. Among them are repaglinide, a rapid-acting prandial insulin ... Cited by 25 - Related articles - BL Direct - All 7 versions
D Duffy, DJ Rader - Current Opinion in Cardiology, 2005 - journals.lww.com Recent findings: In the realm of new high-density lipoprotein-raising therapies,
there is a strong focus on high-density lipoprotein metabolism and the reverse
cholesterol transport pathway. Several infusions of recombinant apoA-I ... Cited by 23 - Related articles - BL Direct - All 4 versions
- ►endojournals.org L Hansen, CT Ekstrom, R Tabanera y … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Activation of peroxisome proliferator-activated receptors (PPARs)- by
thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPAR / agonists
(pargluva, ragaglitazar) is a widely used pharmacological principle to ... Cited by 18 - Related articles - BL Direct - All 2 versions
LA Carlson - Current opinion in cardiology, 2006 - journals.lww.com Recent findings: Treatment of atherosclerotic cardiovascular disease with
nicotinic acid and statin results in a pronounced increase of protective
high-density lipoprotein cholesterol and reduces morbidity/mortality. ... Cited by 16 - Related articles - BL Direct - All 5 versions
JJ Link, A Rohatgi, JA de Lemos - Current Problems in Cardiology, 2007 - Elsevier Numerous epidemiological studies have identified high-density lipoprotein
cholesterol (HDL) to be an independent risk factor for coronary heart disease
(CHD). HDL is an emerging therapeutic target that could rival the impact of ... Cited by 16 - Related articles - All 4 versions
I Gouni-Berthold, W Krone - Current Drug Targets-Cardiovascular &# 38; …, 2005 - ingentaconnect.com Abstract: The peroxisome proliferator-activated receptors (PPARs) , / and are
ligand-activated transcription factors belonging to the nuclear receptor
superfamily. PPARs heterodimerize with the retinoid X receptor (RXR) and ... Cited by 8 - Related articles - BL Direct - All 3 versions
- ►endojournals.org [PDF] L Hansen, CT Ekstrom, RT Palacios, M Anant … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc 1) Novo Nordisk A/S, Bagsværd, Denmark 2) Novo Nordisk Pharmaceuticals Inc,
Princeton, NJ, USA 3) Genaissance Pharmaceuticals, a wholly owned subsidiary of
Clinical Data Inc, New Haven, CT, USA 4) Royal Veterinary and Agricultural ... Related articles
D Duffy, JF Keaney Jr, M Holbrook, N Gokce, PL … - Circulation, 2001 - pt.wkhealth.com Numerous prospective epidemiological studies have shown a strong inverse
relationship between HDL cholesterol (HDL-C) levels and coronary heart disease
(CHD).1 Many controlled clinical trials also demonstrate that treating ... Related articles - All 2 versions